Colorectal cancer
Conditions
Interventions
FOLFOX-Hyperuricemia:No
FOLFOX-Non-Hyperuricemia:No
XELOX-Hyperuricemia:No
XELOX-Non-Hyperuricemia:No
FOLFIRI-Hyperuricemia:No
FOLFIRI-Non-Hyperuricemia:No
Sponsors
School of Chinese Medicine, Southern Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have been diagnosed with colorectal cancer; 2. Patients who received basic chemotherapy (FOLFOX, XELOX or FOLFIRI) after surgery; 3. Patients with baseline uric acid levels after surgery.
Exclusion criteria
Exclusion criteria: 1. Patients with events that significantly affect uric acid levels or taking uric acid-lowering drugs before chemotherapy, such as benzbromarone, probenecid, febuxostat, allopurinol, etc.; 2. Patients with other malignant tumors; 3. Patients with other diseases that seriously affect survival: such as uncontrolled hypertension, severe organ failure, chronic diseases with long-term irregular treatment, etc.; 4. The baseline uric acid value measurement time is more than 7 days from the start of the chemotherapy regimen or the baseline imaging measurement time is more than 8 weeks after the start of the chemotherapy regimen or more than 8 weeks before the start of the chemotherapy regimen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactZhao Xiaoshan
Southern Medical University
Outcome results
None listed